SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed acro

CBIO

Related stories